引用本文:程 香.依达拉奉联合单唾液酸四己糖神经节苷脂钠治疗急性脑梗死的临床疗效观察[J].中国临床新医学,2018,11(8):812-814.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2475次   下载 1506 本文二维码信息
码上扫一扫!
分享到: 微信 更多
依达拉奉联合单唾液酸四己糖神经节苷脂钠治疗急性脑梗死的临床疗效观察
程 香
450006 郑州,河南弘大心血管病医院内一科
摘要:
[摘要] 目的 探讨单唾液酸四己糖神经节苷脂钠及依达拉奉注射液联合治疗急性脑梗死的疗效。方法 选取2016-01~2017-06收治的86例急性脑梗死患者,随机分为两组,每组43例。对照组采用依达拉奉治疗,30 mg/次,2次/d;联合组除给予依达拉奉外,增加单唾液酸四己糖神经节苷脂钠100 mg/次,1次/d。对比两组患者的临床疗效。结果 治疗14 d后,联合组临床疗效明显优于对照组(P<0.05)。入院时,两组患者血清超敏C反应蛋白(hs-CRP)、血清同型半胱氨酸(Hcy)水平,美国国立卫生研究院卒中量表(NIHSS)评分以及改良Barthel指数(BI)评分比较,差异均无统计学意义(P>0.05)。治疗14 d后,两组患者上述指标均优于入院时,且联合组优于对照组(P<0.05)。结论 单唾液酸四己糖神经节苷脂联合依达拉奉治疗急性脑梗死,能够有效提升临床疗效,减轻炎症反应,降低血清Hcy水平,改善患者神经功能,增强日常生活活动能力。
关键词:  单唾液酸四己糖神经节苷脂钠  依达拉奉  急性脑梗死  血清超敏C反应蛋白  血清同型半胱氨酸
DOI:10.3969/j.issn.1674-3806.2018.08.23
分类号:R 743
基金项目:
Clinical effect of edaravone combined with monosialotetrahexosylganglioside sodium on acute cerebral infarction
CHENG Xiang
The First Department of Internal Medicine, the Hongda Cardiovascular Hospital of Henan Province, Zhengzhou 450006, China
Abstract:
[Abstract] Objective To investigate the clinical effect of edaravone combined with monosialotetrahexosylganglioside sodium on acute cerebral infarction. Methods 86 patients with acute cerebral infarction were selected in our hospital from January 2016 to June 2017 and were randomly divided into two groups, with 43 cases in each group. The control group received edaravone(30 mg, ivgtt, bid), and the treatment group received edaravone(30 mg, ivgtt, bid) combined with monosialotetrahexosylganglioside sodium(100 mg, ivgtt, qd) for 14 d. The clinical efficacy was compared between the two groups. Results The curative effect of the treatment group was significantly better than that of the control group(P<0.05). At the time of admission, there were no significant differences in the levels of serum hypersensitive C reactive protein(hs-CRP) and homocysteine(Hcy), NIHSS and BI scores between the two groups(P>0.05). After the treatment, the above indicators were significantly better than those at the time of admission in both of the two groups, and the indicators of the treatment group were significantly better than those of the control group(P<0.05). Conclusion Edaravone combined with monosialotetrahexosylganglioside sodiumcan can significantly improve the clinical efficacy, reduce the inflammatory response and serum Hcy levels, improve the neurological function and enhance the ability of daily activities in the patients with acute cerebral infarction.
Key words:  Monosialotetrahexosylganglioside sodium  Edaravone  Acute cerebral infarction  Serum hypersensitive C reactive protein(hs-CRP)  Serum homocysteine